New electric pulse procedure could tame AFib in heart failure patients

NCT ID NCT07385417

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This pilot study is testing a new procedure called electroporation ablation (using the FARAPULSE system) to treat atrial fibrillation in 200 people who also have heart failure with preserved ejection fraction. Half will get the procedure, half will get standard medical care. The goal is to see if the procedure reduces hospitalizations, strokes, and other serious events. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
electroporation ablation (FARAPULSE procedure)
What this could lead to
If successful, this could offer a more effective way to control atrial fibrillation in people with heart failure, potentially reducing hospital visits and complications.
What could go wrong
This is a small, early pilot study, so results may not apply broadly. The procedure carries risks like bleeding, nerve injury, or heart damage, and it's unclear if it will outperform standard medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cardioangiologisches Centrum Bethanien

    RECRUITING

    Frankfurt am Main, 60431, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.